Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Novo’s Obesity Med Wegovy Skips Listing Again in August
August 24, 2023
- Japan Designates Loxoprofen Cold Meds as Behind the Counter Drugs
August 23, 2023
- Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
August 23, 2023
- Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
August 23, 2023
- MHLW Generics Study Group Discusses Yardsticks to Gauge Manufacturers’ Efforts towards Stabilizing Supplies
August 22, 2023
- Relief Claims OK’ed for 9 More Deaths after COVID Vaccination
August 22, 2023
- Japan Panel OKs Novartis’ siRNA Dyslipidemia Therapy and More
August 22, 2023
- Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
August 22, 2023
- New HIV Cases Reported in 2022 Hit 20-Year Low
August 21, 2023
- MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
August 21, 2023
- MEXT Pushes Joint Negotiations for Drug Purchases at University Hospitals
August 17, 2023
- GSK’s Arexvy, 1st RSV Vaccine, Up for Japan Panel Review on Aug. 28
August 16, 2023
- Govt to Properly Discuss Public Funding for COVID Drugs after October: Minister
August 16, 2023
- Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
August 16, 2023
- Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
August 10, 2023
- Japan Panel OKs Rollout of XBB.1.5-Based COVID Vaccines on Sept. 20
August 10, 2023
- Japan’s Pandemic Response Agency Officially Set to Launch on September 1
August 10, 2023
- Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
August 9, 2023
- MHLW Panel OKs Online Sales of Behind-the-Counter Drugs, but with Pharmacists’ Online Supervision
August 9, 2023
- Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
August 8, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…